scientific program - World Allergy Organization

More documents

Recommendations

Info

8 sneezing runny nose itchy nose itchy eyes Presentation: 10 mg cetirizine dihydrochloride white film-coated tablet with breakline. Uses: Treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. Dosage and administration: Adult and children over 6 years: 10mg daily. In patients with moderate to severe renal impairment, adapt dosage. Contra-indications: Hypersensitivity to constituents and patients with severe renal impairment at less than 10ml/min creatinine clearance. Avoid use in pregnancy and during lactation. Precautions: Do not exceed recommended dose if driving or operating machinery. Drug interactions: to date no known interactions with other drugs. As with other antihistamines avoid excessive alcohol consumption. Side effects: fatigue, mild to transient somnolence, headache, dizziness, agitation, dry mouth and gastrointestinal discomfort have been reported. Once-a-day Cetirizine dihydrochloride A L L E R G Y Take control of your allergy. Fast EURO RSCG LIFE ★
65-4573-00-5 ® ZYRTEC ® (cetirizine hydrochloride) Tablets and Syrup For Oral Use DESCRIPTION Cetirizine hydrochloride, the active component of ZYRTEC ® tablets and syrup, is an orally active and selective H1-receptor antagonist. The chemical name is (±) - [2- [4- [ (4-chlorophenyl)phenylmethyl] -1- piperazinyl] ethoxy]acetic acid, dihydrochloride. Cetirizine hydrochloride is a racemic compound with an empirical formula of C21H25ClN2O3•2HCI. The molecular weight is 461.82 and the chemical structure is shown below: Cl– CH - N N - CH 2 - CH 2 - O - CH 2 - COOH . 2HCl Cetirizine hydrochloride is a white, crystalline powder and is water soluble. ZYRTEC tablets are formulated as white, filmcoated, rounded-off rectangular shaped tablets for oral administration and are available in 5 and 10 mg strengths. Inactive ingredients are: lactose; magnesium stearate; povidone; titanium dioxide; hydroxypropyl methylcellulose; polyethylene glycol; and corn starch. ZYRTEC syrup is a colorless to slightly yellow syrup containing cetirizine hydrochloride at a concentration of 1 mg/mL (5 mg/5 mL) for oral administration. The pH is between 4 and 5. The inactive ingredients of the syrup are: banana flavor; glacial acetic acid; glycerin; grape flavor; methylparaben; propylene glycol; propylparaben; sodium acetate; sugar syrup; and water. CLINICAL PHARMACOLOGY Mechanism of Actions: Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In clinical studies, however, dry mouth was more common with cetirizine than with placebo. In vitro receptor binding studies have shown no measurable affinity for other than H1 receptors. Autoradiographic studies with radiolabeled cetirizine in the rat have shown negligible penetration into the brain. Ex vivo experiments in the mouse have shown that systemically administered cetirizine does not significantly occupy cerebral H1 receptors. Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (Tmax) of approximately 1 hour following oral administration of tablets or syrup in adults. Comparable bioavailability was found between the tablet and syrup dosage forms. When healthy volunteers were administered multiple doses of cetirizine (10 mg tablets once daily for 10 days), a mean peak plasma concentration (Cmax) of 311 ng/mL was observed. No accumulation was observed. Cetirizine pharmacokinetics were linear for oral doses ranging from 5 to 60 mg. Food had no effect on the extent of cetirizine exposure (AUC) but Tmax was delayed by 1.7 hours and Cmax was decreased by 23% in the presence of food. Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25-1000 ng/mL, which includes the therapeutic plasma levels observed. Metabolism: A mass balance study in 6 healthy male volunteers indicated that 70% of the administered radioactivity was recovered in the urine and 10% in the feces. Approximately 50% of the radioactivity was identified in the urine as unchanged drug. Most of the rapid increase in peak plasma radioactivity was associated with parent drug, suggesting a low degree of first-pass metabolism. Cetirizine is metabolized to a limited extent by oxidative O-dealkylation to a metabolite with negligible antihistaminic activity. The enzyme or enzymes responsible for this metabolism have not been identified. Elimination: The mean elimination half-life in 146 healthy volunteers across multiple pharmacokinetic studies was 8.3 hours and the apparent total body clearance for cetirizine was approximately 53 mL/min. Interaction Studies Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin. No interactions were observed. In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed. The disposition of theophylline was not altered by concomitant cetirizine administration. Special Populations Pediatric Patients: When pediatric patients aged 7 to 12 years received a single, 5-mg oral cetirizine capsule, the mean Cmax was 275 ng/mL. Based on cross-study comparisons, the weight-normalized, apparent total body clearance was 33% greater and the elimination half-life was 33% shorter in this pediatric population than in adults. In pediatric patients aged 2 to 5 years who received 5 mg of cetirizine, the mean Cmax was 660 ng/mL. Based on cross-study comparisons, the weight-normalized apparent total body clearance was 81 to 111% greater and the elimination half-life was 33 to 41% shorter in this pediatric population than in adults. In pediatric patients aged 6 to 23 months who received a single dose of 0.25 mg/kg cetirizine oral solution (mean dose 2.3 mg), the mean Cmax was 390 ng/mL. Based on cross-study comparisons, the weight-normalized, apparent total body clearance was 304% greater and the elimination half-life was 63% shorter in this pediatric population compared to adults. The average AUC(0-t) in children 6 months to
Page 1: FINAL PROGRAM World Allergy Organiz
Page 4 and 5: 2 WAO Congress-XVIII ICACI Final Pr
Page 6 and 7: 4 World Allergy Organization (WAO)-
Page 8 and 9: 6 WAO Congress-XVIII ICACI Final Pr
Page 12 and 13: 10 PRECAUTIONS (continued) ADVERSE
Page 14 and 15: 12 WAO Congress-XVIII ICACI Final P
Page 23 and 24: WAO Congress-XVIII ICACI Final Prog
Page 25 and 26: Whistler alpine resort WAO Congress
Page 29 and 30: XXIII EAACI Congress 12-16 June 200
Page 31 and 32: 7:00 8:00 9:00 10:00 11:00 12:00 13
Page 49 and 50: WEDNESDAY WEDNESDAY SEPTEMBER SEPTE
Page 51 and 52: www.annualmeeting.aaaai.org Visit w
Page 59 and 60: Presenting authors indicated in bol
Page 61 and 62:
FRIDAY, 12 SEPTEMBER WAO Congress-X
Page 63 and 64:
Imagine research targeting IgE, a k
Page 65 and 66:
WAO Congress-XVIII ICACI Final Prog
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 98 and 99:
96 PLAN TO ATTEND! SOYEZ DES NÔTRE
Page 100 and 101:
98 Dolovich, Myrna Canada BR86 Dubo
Page 102 and 103:
100 Schnuch, Axel Germany BR88 Scho
Page 104 and 105:
102 201 ACII - Journal of the World
Page 106 and 107:
104 WAO Congress-XVIII ICACI Final
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
114 Crowne Plaza Hotel Georgia 801
Page 118 and 119:
Page 120 and 121:
118 (salmeterol xinafoate/fluticaso
Page 122 and 123:
COPD, the most commonly reported dr
Page 124 and 125:
Page 126 and 127:
124 Seaplane landing at sunset Gran
Page 128:
DS2 - Dinner Symposium Monday, 8 Se
show all

scientific program - World Allergy Organization

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?